We are pleased to announce the 3rd Annual Innovations Against AMR event, taking place place on Wednesday 20th November at Enterprise Wharf in Birmingham.
The event is running during World Antimicrobial Resistance Awareness Week (WAAW), a global campaign to raise awareness of antimicrobial resistance and encourage best practices to prevent the spread of drug-resistant infections. The Theme for WAAW 2024 is “Educate. Advocate. Act now”.
This year, our Innovations Against AMR Event is focused on novel developments within the field of combating AMR throughout the UK, with a special focus on small and medium enterprises. We are interested in hearing from companies in various stages of spinning out and developing their ideas and providing a platform for discussion, collaborations and advocacy against AMR.
This event has grown year on year, bringing together innovators, researchers and other stakeholders working in this sector and has proven a great opportunity for networking and building collaborations. Medilink Midlands are pleased to be partnering with WMHTIA, Bruntwood, Cytecom and the newly established UKRI AMR Network – ARREST AMR to deliver this event:
- WMHTIA provides companies access to services and expertise that are essential in critically developing technologies.
- Medilink Midlands provides support services to healthcare businesses in the Midlands region, including networking opportunities, business development advice, and access to funding.
- Bruntwood SciTech is a property and innovation company that provides flexible workspace and support services to science and technology businesses.
- Cytecom is a pioneering SME that has developed a rapid method for diagnosing bacterial infections and advocates for raising awareness about antimicrobial resistance.
- The ARREST-AMR (Accurate, Rapid, Robust, and Economical One Health Diagnostics for antimicrobial resistance) network will work alongside seven other networks to bring together diverse expertise from academia, industry, government, regulatory agencies, and charities. They will foster collaborations, drive innovation, and develop effective strategies for implementing fit-for-purpose One Health AMR Diagnostics.
5 Reasons to Attend the 3rd Annual Innovations Against AMR Event
1. Be at the forefront of AMR innovation: Connect with leading innovators, researchers, and industry experts driving advancements in combating antimicrobial resistance. Discover the latest breakthroughs and explore potential collaborations.
2. Support SMEs and foster growth: Learn about innovative solutions developed by small and medium enterprises (SMEs) and contribute to their success. Network with like-minded individuals to create new partnerships and drive innovation.
3. Gain valuable insights and knowledge: Attend engaging presentations and discussions on the latest trends and challenges in the field of AMR. Expand your understanding of the issue and stay ahead of the curve.
4. Network with key stakeholders: Connect with representatives from organisations like Medilink Midlands, WMHTIA, Bruntwood, Cytecom, and the ARREST-AMR network. Build relationships and explore potential partnerships.
5. Contribute to a global cause: Join the fight against antimicrobial resistance by attending this event. Be part of a community dedicated to raising awareness, promoting best practices, and driving positive change.
CLICK TO BOOK YOUR PLACE HERE.
Agenda
10:00am Registration
10:30am Opening Remarks
10:50am Session 1: Understanding and Tackling the Multidimensional Challenges of AMR
11:05am Arrest AMR Network Introduction
11:35am Role of AMR Diagnostics in Primary Care
11:50am Comfort break
12pm Showcase of Innovators
12:30pm Lunch break
1:15pm Session 2: From Concept to Commercial
2:15pm Showcase of Innovators
2:45pm National Biofilm Innovation Centre
3:15pm Closing Remarks followed by networking
4:30pm Depart
Speaker Information
Dr Enrico Marsili
Dr Enrico Marsili received his PhD in Chemical Engineering from the University of Rome, Italy. After postdoctoral research at University of Minnesota, he took a Lecturer position at Dublin City University. In 2012, he joined the newly formed Singapore Centre for Environmental Life Sciences Engineering, Singapore, as Principal Scientist. In 2019, he moved to Nazarbayev University as Associate Professor in the Department of Chemical and Materials Engineering. Since 2022, he is Associate Professor in Life Sciences and Healthcare at University of Nottingham, Ningbo, China. His research focuses on the characterisation of mixed biofilms using electrochemical methods and the development of novel bioprocess for efficient biosynthesis of commodity chemicals in biofilms. He collaborates with several institutions in China, such as South China University of Technology (SCUT), Shenzhen Institute of Advanced Technology (SIAT) and Shanghai Institute of Materia Medica (SIMM). He has received competitive funding from Collaborative Research Programme and Marine Research Program (National Research Foundation, Singapore), Public Utility Board, Singapore, and municipal level funding (Ningbo, China).
Dr Philip Turner
Dr Philip Turner is a senior researcher in the Infections, Respiratory and Acute care Research Group and the Head of Operations of the HealthTech Research Centre in Community Healthcare (Oxford Health NHS Foundation Trust) based at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. His research interests include the diagnosis and management of common infections and approaches to antimicrobial stewardship in community healthcare settings. Recent activities include co-leadership of the RAPTOR-C19 evaluations of point-of-care tests for SARS-CoV-2 and other respiratory viruses in community care, trial management support for the trans-European VALUE-Dx PRUDENCE RCT of the clinical and cost-effectiveness of diagnostic interventions for RTI, and co-investigation on the NIHR and NHSE-funded TOUCAN evaluation of novel diagnostics for acute uncomplicated UTI.
Dr Abigail Moore
Dr Abi Moore is a practicing GP in London and a clinical researcher in the Infections, Respiratory and Acute Care Research Group based at the Nuffield Department of Primary Care Health Sciences at the University of Oxford. Abi has a clinical and research interest in the care of older people in care homes. Her PhD is on understanding acute functional decline and its relationship to urinary tract infections in this patient group. Abi is co-lead of the DISCO UTI study which is developing new ways to accurately diagnose UTI in care home residents, including approaches incorporating novel diagnostic tests.
To read more about Medilink Midlands’ role within the WMHTIA project, click here.
For more information on the wider project, click here to visit the WMHTIA website.
This event forms part of the West Midlands Health Tech Innovation Accelerator (WMHTIA) event series. Medilink Midlands are one of a consortium of delivery partners for the WMHTIA, a project funded by the Department for Science, Innovation and Technology, Innovate UK and West Midlands Combined Authority (part of City Regions).
